AB1020 OSTEOPOROSIS’S PARTICULARITIES IN BREAST CANCER PATIENTS UNDER AROMATASE-INHIBITORS
Authors: F. Idrissi Zaki, H. Tebaa, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2022)

Background Breast cancer is the first female cancer, especially after menopause. In Morocco its prevalence is estimated at 35.8%. Its hormone-dependent aspect requires the use of hormone-modulating treatments, in particular aromatase-inhibitors responsible for hypogonadism, bone loss and osteoporosis (OP) with increased fracture risk. Objectives The aim of this study is to determine the epidemiological, clinical and densitometric profile of osteoporotic patients with breast cancer under aromatase-inhibitors and to evaluate the factors associated with bone gain in this population. Methods This is a descriptive and analytical retrospective study of 126 osteoporotic patients with breast cancer under aromatase-inhibitors, collected during a period of 4 years (2017 to 2021). Statistical data analysis was performed using SPSS version 20 software. The bivariate study was performed by ANOVA test. Results All the patients were treated for breast cancer and received systemic hormone-modulating anti-aromatase type therapy. All the patients had densitometric osteoporosis confirmed by a T score &lt; or equal to −2.5, of which 31.7% had a T-score &lt; or equal to -3.5. The average age was 62.29 (40–92) years. 1.6% had an osteoporosis family history and 0.8% had an osteoporosis’s fracture family history, 77% had a personal history of fracture. 54.8% were overweight, 14.3% had a metastasis. 88.1% had insufficient vitamin D levels (&lt;20 ng/L). 15.9% had high blood pressure. The average duration of anti-osteoporotic treatment was 2.31 years. 77% of patients were on Residronate, 8.7% on Zoledronate, and 14.3% on Alandronate. The study of bone gain involved patients who had an evaluation of osteodensitometry whithin 2 years, the average spine bone gain was 0.011 and 0.018 for femur bone gain. In bivariate analysis, they were a statistically significant association between the presence of a T-Score value &lt;-3.5 and spine bone gain (p=0.035), the absence of metastasis with femur bone gain (p&lt;0.0001), the absence of hypertension and femur bone gain (p=0.015), concerning the therapeutic means used there were an association between the use of zoledronic acid and spine bone gain (p =0.021). Conclusion Breast cancer patients under aromatase-inhibitors are particularly prone to osteoporosis, hence the interest of paying close attention to this population and intervening on the associated modifiable factors for better management. References [1]Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, et al. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. Cancer. 2017 Jul 1;123(13):2444-51. [2]van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, et al. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. Breast Cancer Res Treat. 2020 Apr;180(3):675-85. [3]Body J. Aromatase inhibitors-induced bone loss in early breast cancer. BoneKEy Reports. 2012 Oct 3;1:201. Disclosure of Interests None declared